ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,870.62
      -1.32%
      US Tech 100
      19,880.00
      -2.30%
      Dow Jones
      43,444.99
      -0.70%
      Brent Oil
      70.895
      0.00%
      Bitcoin
      91,356.13
      0.32%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Geron Corp (GERN) Quote

      Geron Corp

      Geron Corp (GERN)

      NASDAQ
      3.66
      -0.05
      (-1.35%)
      Closed November 16 4:00PM
      Delayed by 15 minutes
      3.70
      0.04
      (1.09%)
      After Hours: 7:45PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      3.70
      Bid
      3.66
      Ask
      3.70
      Volume
      10,276,543
      3.63 Day's Range 3.78
      1.64 52 Week Range 5.34
      Market Cap
      2.23B
      Previous Close
      3.71
      Open
      3.7443
      Last Trade
      100
      @
      3.7
      (formt)
      Last Trade Time
      Financial Volume
      $ 37,936,024
      VWAP
      3.6915
      Average Volume (3m)
      8,361,146
      Shares Outstanding
      602,795,563
      Dividend Yield
      -
      PE Ratio
      -11.98
      Earnings Per Share (EPS)
      -0.31
      Revenue
      237k
      Net Profit
      -184.13M

      About Geron Corp

      Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a ... Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.geron.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Geron Corp is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GERN. The last closing price for Geron was $3.71. Over the last year, Geron shares have traded in a share price range of $ 1.64 to $ 5.34.

      Geron currently has 602,795,563 shares outstanding. The market capitalization of Geron is $2.24 billion. Geron has a price to earnings ratio (PE ratio) of -11.98.

      Ask ADVFN Intelligence (AI)

      Geron (GERN) Options Flow Summary

      GERN Options Flow

      Overall Flow

      Bullish

      Net Premium

      30k

      Calls / Puts

      100.00%

      Buys / Sells

      0.00%

      OTM / ITM

      100.00%

      Sweeps Ratio

      0.00%

      GERN Latest News

      More News

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors

      November 14 2024
      Edgar (US Regulatory)

      Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

      Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D...

      November 11 2024
      Business Wire

      Geron to Participate in the Stifel 2024 Healthcare Conference

      Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024...

      November 11 2024
      Business Wire

      Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million

      RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma’s synthetic...

      November 07 2024
      GlobeNewswire Inc.

      Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors

      Geron received $250 million in gross proceeds at closing, with access to an additional $125 million in debt Strengthens balance sheet to support the commercial launch of RYTELO™ in the U.S. and...

      November 07 2024
      Business Wire

      Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of sales Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty...

      November 07 2024
      Business Wire

      Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies

      New analyses from the IMerge clinical trial suggest that imetelstat demonstrates clinical activity in patients with lower-risk MDS with transfusion-dependent anemia regardless of prior therapy...

      November 05 2024
      Business Wire

      Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 680,220 shares of Geron...

      October 17 2024
      Business Wire

      Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024

      Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the...

      October 15 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.49-11.69451073994.194.333.63107021603.98575831CS
      4-0.36-8.866995073894.064.463.6393430854.12181131CS
      12-0.82-18.14159292044.524.8253.6383611464.31147419CS
      26-0.05-1.333333333333.755.343.2399934864.41983607CS
      521.7892.70833333331.925.341.6497466353.60592608CS
      1562.11132.7044025161.595.340.989963227693.01490666CS
      2602.33170.0729927011.375.340.7550729412.67245119CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CEROCERo Therapeutics Holdings Inc
      $ 0.2853
      (52.40%)
      		1.17B
      CYCNCyclerion Therapeutics Inc
      $ 2.5306
      (42.97%)
      		11.99M
      SPPLSIMPPLE Ltd
      $ 1.2503
      (41.60%)
      		165.69M
      PULMPulmatrix Inc
      $ 6.5586
      (39.54%)
      		5.37M
      ZTEKZentek Ltd
      $ 1.2574
      (29.96%)
      		309.67k
      TFFPTFF Pharmaceuticals Inc
      $ 0.376101
      (-76.49%)
      		9.35M
      EYENEyenovia Inc
      $ 0.10185
      (-70.05%)
      		52.8M
      CTXRCitius Pharmaceuticals Inc
      $ 0.1974
      (-39.89%)
      		11.26M
      VVPRVivoPower International PLC
      $ 0.8151
      (-39.62%)
      		2.34M
      IPWiPower Inc
      $ 0.7302
      (-39.15%)
      		1.15M
      CEROCERo Therapeutics Holdings Inc
      $ 0.2853
      (52.40%)
      		1.17B
      ELABElevai Labs Inc
      $ 0.0211
      (-19.47%)
      		380.03M
      NVDANVIDIA Corporation
      $ 141.98
      (-3.26%)
      		253.02M
      SPPLSIMPPLE Ltd
      $ 1.2503
      (41.60%)
      		165.69M
      STISolidion Technology Inc
      $ 0.44
      (25.71%)
      		140.02M

      GERN Discussion

      View Posts
      Spike5 Spike5 16 hours ago
      Oh my it looks like we and I were correct . Too bad you let a spellcheck changing well to we dissuade getting rid of this crap
      👍️0
      Stumblebum Stumblebum 4 days ago
      Hey it’s the “we I hope hope you read” is back …what have you and Jethro been up to
      👍️0
      Spike5 Spike5 5 days ago
      Not even trump can save this useless pile of trash
      👍️0
      learningcurve2020 learningcurve2020 1 week ago
      Shrugs. LP's got the greatest job in the world.  
      👍️0
      learningcurve2020 learningcurve2020 1 week ago
      Like I said here many times I've been comparing Geron's "By the book" approach to LP's bizarre approach.  Geron is now the clear winner. 

      >>"This has been a transformative year for Geron, following our first FDA approval and commercial launch of RYTELO in June. The initial full quarter of product revenue from our U.S. launch exceeded our expectations and demonstrates strong execution as a commercial company.



      >>In November 2024, completed synthetic royalty and debt financing transactions to strengthen our cash position and further solidify our balance sheet while providing strategic flexibility to invest in our future. We entered into a synthetic royalty agreement with Royalty Pharma providing $125 million of capital in exchange for tiered royalty payments. We also entered into a 5-year, senior term loan agreement with Pharmakon for up to $250 million, from which we have drawn a first tranche of $125 million, a portion of which was used to fully repay amounts owed under our existing loan with Hercules Capital, Inc. and Silicon Valley Bank ($86.5 million), which has now been terminated, with the ability to borrow another $125 million prior to the end of 2025, subject to specified conditions.
      👍️0
      learningcurve2020 learningcurve2020 1 week ago
      Wow, nice!

      Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of salesReceived $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
      👍️0
      Stumblebum Stumblebum 2 weeks ago
      You need to reread your post 7806….quote and “yes this is a cancer cure”…..that’s ok dude I understand …..that’s what happens when you sit next to Jerhro Bodine
      👍️0
      Stumblebum Stumblebum 2 weeks ago
      You said and I quote “ we I hope hope you read “…...and you talk about first grade education…..bhawhahahahahahahahaha
      👍️0
      Spike5 Spike5 2 weeks ago
      We I hope hope you read the message I wrote making a complete fool of you over the cure . When you get that first grade education let me know moron .
      👍️0
      Stumblebum Stumblebum 2 weeks ago
      There he is the basher man…..was expecting to hear from you since the stock is down today …..you must of been bored the last few days when Gern went up a bit ….bhawhahahaahahahaha
      👍️0
      Spike5 Spike5 2 weeks ago
      This board is doing exactly what it should be doing shutting the hell up … there is no defending this garbage company
      👍️0
      learningcurve2020 learningcurve2020 3 weeks ago
      It may be a quarter too early for that information.  I hope to hear that few patients are complaining about side effects or stopping treatment.  The revs will then follow.  

      28% (n=33 out of 118) of patients taking RYTELO required ZERO red blood cell transfusions for 24 consecutive weeks or more vs 3% (n=2 out of 60) of patients taking placebo
      👍️0
      big bambino big bambino 3 weeks ago
      Agreed, should be interesting heading to there, best to us all
      👍️0
      Stumblebum Stumblebum 3 weeks ago
      Regarding earnings in two weeks…..I want to see increased revenues for rytelo …..that’s key and also and updates on European approval
      👍️0
      big bambino big bambino 3 weeks ago
      picked up another 1k@4.03. Might use as swing or hold onto longer. Depending on what the earnings report has to say about their future plane's
      👍️0
      Spike5 Spike5 4 weeks ago
      Oh wow ! This is done it will be in the twos by mid November. People on this board think they proved me wrong because I jokingly use the word cure . Anyone with a first grade education knows there is no cure for any cancer . What you can’t prove me wrong on is this is a poorly run company with a drug that very few people have a need for .
      👍️0
      learningcurve2020 learningcurve2020 4 weeks ago
      Grrrrron back in the 3's.  Come on already! 
      👍️0
      big bambino big bambino 4 weeks ago
      I haven't heard anything yet, 🤔
      👍️0
      Stumblebum Stumblebum 4 weeks ago
      Well no news yes….but earnings first week of November…..what about European imetelstat approval?
      👍️0
      big bambino big bambino 4 weeks ago
      Sorry 3k @ 4.04, for transparency
      👍️0
      big bambino big bambino 4 weeks ago
      Picked up 3k. Massive swing with no news what so ever.
      👍️0
      Stumblebum Stumblebum 4 weeks ago
      That’s all nice but currently under $4 🤮🫣
      🤫 1
      learningcurve2020 learningcurve2020 4 weeks ago
      "Scotiabank Initiates Geron at Sector Outperform With $6 Price Target"


      Geez, this stock never disappoints. Eye rolls.



      >>Geron (GERN) has an average buy rating and a price target range of $5.50 to $10, according to analysts polled by Capital IQ.
      👍️0
      seward seward 4 weeks ago
      Bought small shares to flip.
      👍️0
      Stumblebum Stumblebum 1 month ago
      I did prove you wrong no where in Geron website nor info. On imetelstat does the word cure used….nice try though…..stick with bashing
      👍️0
      Spike5 Spike5 1 month ago
      Funny I do not need to prove you wrong , you need to prove me wrong . Oh here is your apology, sorry YOU LOSE! Haha
      👍️0
      Stumblebum Stumblebum 1 month ago
      Oh and spike so there is no hard feeling ….no need to apologize
      👍️0
      Stumblebum Stumblebum 1 month ago
      Hey it’s the market maker basher again…..tell me dude where does geron say that imetelstat CURES cancer…..maybe it says can stop the spread and division of cells….NO where does it uses the word CURE….but nice try anyway….
      👍️0
      Spike5 Spike5 1 month ago
      WOW!!!! Longs should be absolutely irate over this stock …. How many effing years has this been and it cannot even get to 5 after fda approval .
      👍️0
      Spike5 Spike5 1 month ago
      1/4 step forward and then 3 steps back . Total joke yes this is a cancer cure haha
      👍️0
      Spike5 Spike5 1 month ago
      It’s over shorts will win like I have said all along … this is done I told people what a shit company this is
      👍️0
      Spike5 Spike5 1 month ago
      If it goes under 4 it will do a RS within one year .
      👍️0
      learningcurve2020 learningcurve2020 1 month ago
      Everyone's just waiting to see if there's any market penetration. Retail will be the last to know either way.
      👍️0
      Spike5 Spike5 1 month ago
      This company can’t even cure its own cancer . Management
      👍️0
      big bambino big bambino 1 month ago
      Seeing all this price swing back and forth (with no announcement) gives credence to manipulation. JUST MY HONEST OPINION!
      👍️0
      attilathehunt attilathehunt 2 months ago
      Probably funds reshuffling for quarter end.
      👍️0
      big bambino big bambino 2 months ago
      1 1/2 hours into overtime, 550,000 shares traded, ummmmmmmmmm
      👍️0
      Stumblebum Stumblebum 2 months ago
      The dude had the day off Gern up 8%….
      👍️ 1 😀 2 🤣 1
      Stumblebum Stumblebum 2 months ago
      He probably works at a market maker and gets paid to bash the stock cause his employer is shorting the shares…..that’s his job
      👍️ 3
      luckygm luckygm 2 months ago
      Instead of complaining all the time, why don't you buy down here at sell when it goes up 10%. You could have made a fortune doing that over the past 6 months.
      👍️0
      Spike5 Spike5 2 months ago
      Wow 10 % loss is a disaster . Now you know why I have not one good thing to say about this company . Management is making a killing and killing longs in the process .
      👍️0
      Spike5 Spike5 2 months ago
      This very well may be the dam breaking today … the shorts are going to keep driving this down to nothing . It’s a shame because this could have been a good thing but it is so poorly run and they have no news on anything coming out anytime soon . This amazes me that it cannot even get above five and now it’s going under 4 . Maybe even today
      👍️0
      Stumblebum Stumblebum 2 months ago
      These new hires are probably salespeople to push the imetelstat drug
      👍️0
      Stumblebum Stumblebum 2 months ago
      IMO a BO will occur next spring or summer once there is a definitive record of sales and forecast profitability…..$10 a share would be nice at the minimum
      👍️0
      attilathehunt attilathehunt 2 months ago
      Those new stock options announced after the close for newly hired 'ee's are an incentive to stay on in the very likely event of a BO...

      They will need them to stay on to ensure an orderly transition.

      BO before end of year is my prediction.
      👍️ 2
      big bambino big bambino 2 months ago
      closer & closer
      👍️0
      big bambino big bambino 2 months ago
      getting closer 7 closer to that sub $4 mark
      👍️0
      Stumblebum Stumblebum 2 months ago
      Ya they’re a bunch of bashing wussies
      👍️0
      learningcurve2020 learningcurve2020 2 months ago
      These weepers are so lazy they don't even post the news.

      >>We are thrilled to welcome Jim at this critical time when RYTELO is commercially available in the U.S. and we are seeing encouraging uptake since its launch at the end of June 2024,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer
      👍️0
      big bambino big bambino 2 months ago
      This is why I pay no attention to these weeping little girls on this board. One day movement down and "the sky is falling, cash out before it goes below $4". From June price of approx $3,40 (per-approval) to today's price of $4.60, is what about 30% increase. So with no news it fluctuates from $4.70 - $4.20 (with no manipulation at all, ha). I don't need to post daily fluctuations because I'm not looking to influence anyone. I've been here long enough to wait a few more months to see direction. The one thing I do know is, this drug is a one of a king, with phenomenal results and in due time will produce results. If your a day trader, go for it. So much quieter with my ignore button 🤣
      👍️0

      Your Recent History

      NASDAQ
      GERN
      Geron
      NYSE
      PACS
      PACS
      TG
      APPH
      Apontis Pharma
      LSE
      MMS
      Ly Emu Small
      Delayed Upgrade Clock